IDSA : View All FDA Alerts

Print

ShareThis
Text Size

View All FDA Alerts
Search More FDA
05/19/2016
Nizoral ketoconazole Oral Tablets: Prescribing for Unapproved Uses including Skin and Nail Infections Continues; Linked to Patient Death
FDA Alert
02/27/2012
FDA Approves First H. pylori Breath Test for Children
FDA Alert
01/04/2012
FDA Expands Use of Prevnar 13 Vaccine for People Ages 50 and Older
FDA Alert
11/18/2011
FDA Approves First Supplemental Test for Chagas Disease
FDA Alert
10/25/2011
Xigris [drotrecogin alfa (activated)]: Market Withdrawal - Failure to Show Survival Benefit
FDA Alert
09/28/2011
FDA Clears First Single Use Face Mask for Children
FDA Alert
09/13/2011
FDA Investigates Multistate Outbreak of Listeriosis
FDA Alert
09/08/2011
Tumor Necrosis Factor-alpha Blockers: Label Change - Boxed Warning Updated for Risk of Infection from Legionella and Listeria
FDA Alert
08/03/2011
Diflucan (fluconazole): Long-term, High-dose Use During Pregnancy May Be Associated With Birth Defects
FDA Alert
FDA issues final rule on safety and effectiveness of antibacterial soaps
FDA Alert
FDA Advises Testing for Zika Virus in All Donated Blood in the US
FDA Alert
July 2016 Safety Labeling Changes posting includes 52 products
FDA Alert
FDA approves first generic version of widely used influenza drug
FDA Alert
Fluoroquinolone Antibacterial Drugs for Systemic Use: Drug Safety Communication - Warnings Updated Due to Disabling Side Effects
FDA Alert
FDA announces voluntary nationwide recall of oral liquid docusate sodium manufactured by PharmaTech and distributed by Rugby Laboratories
FDA Alert
Stӧckert 3T Heater-Cooler System by Sorin Group Deustchland GmbH: Safety Communication - Reports of Mycobacterium Chimaera Infections
FDA Alert
Fluoroquinolone Antibacterial Drugs: Drug Safety Communication - FDA Advises Restricting Use for Certain Uncomplicated Infections
FDA Alert
FDA Evaluating Study Examining Use of Oral Fluconazole (Diflucan) in Pregnancy
FDA Alert
Focus Diagnostics Laboratory Examination Kits: Class I Recall - Inaccurate Test Results
FDA Alert
FDA approves new treatment for inhalation anthrax
FDA Alert
Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Fluconazole Injection
FDA Alert
FDA approves new drug for treatment of chronic hepatitis C genotypes 1 and 4
FDA Alert
L.G Compounded Asafoetida Powder Recall
FDA Alert
Kaletra product labeling was updated
FDA Alert
Product Remova/lFoodborne Illness Outbreak Investigation Advisory
FDA Alert
FDA approves new antifungal drug Cresemba
FDA Alert
FDA approves new antibacterial drug Avycaz
FDA Alert
New data shows test can help physicians remove patients with suspected TB from isolation earlier
FDA Alert
Approval changes to the Kaletra label
FDA Alert
FDA approves a second vaccine to prevent serogroup B meningococcal disease
FDA Alert
Don't Inject Patients with IV solutions from Wallcur
FDA Alert - updated 1/14/15
FDA approves new antibacterial drug Zerbaxa
FDA Alert
FDA approves Viekira Pak to treat hepatitis C
FDA Alert
Dietary Supplements Containing Live Bacteria or Yeast in Immunocompromised Persons: Warning - Risk of Invasive Fungal Disease
FDA Alert
FDA approves Gardasil 9 for prevention of HPV
FDA Alert
First vaccine approved by FDA to prevent serogroup B Meningococcal disease
FDA Alert
Cubist Pharmaceuticals Issues Voluntary U.S. Recall Of Certain Lots Of CUBICIN
FDA Alert
FDA approves Orbactiv to treat skin infections
FDA Alert
FDA Approves Sivextro to Treat Skin Infections
FDA Alert
HIV/AIDS Update - Revised HHS Adult and Adolescent Antiretroviral Treatment Guidelines available
FDA Alert
FDA approves new treatment for hepatitis C virus
IDSA Continues to Recommend Antivirals for Influenza
IDSA continues to recommend the use of neuraminidase inhibitor antiviral drugs in the treatment of influenza.
Alert: FDA Statement about Product Quality of Parenteral Vancomycin Products
Drug Interactions: Victrelis (boceprevir) and Ritonavir-Boosted Human Immunodeficiency Virus (HIV) Protease Inhibitor Drugs
FDA Alert
Drug Safety Communication: Statins and HIV or Hepatitis C Drugs - Interaction Increases Risk of Muscle Injury (Content)
FDA Alert
Drug Safety: Clostridum difficle-Associated Diarrhea Can Be Associated with Proton Pump Inhibitors (PPIs)
FDA Alert
Facts about Victrelis (boceprevir) and HIV protease inhibitors
Facts about Victrelis (boceprevir) and HIV protease inhibitors Victrelis is a hepatitis C virus (HCV) protease inhibitor used with the medicines peginterferon alfa and ribavirin to treat chronic (long lasting) hepatitis C infection in adults who have not
FDA Safety Communication: Risk of Bacterial Contamination with Other-Sonic Generic Ultrasound Transmission Gel
FDA Statement about Product Quality of Parenteral Vancomycin Products
FDA Alert
Zithromax (azithromycin): FDA Statement on risk of cardiovascular death

| HIVMA | Contact Us

© Copyright IDSA 2016 Infectious Diseases Society of America

Full Site Mobile Site